Molecular targets for cancer therapy and prevention

被引:12
作者
Gazdar, AF [1 ]
Miyajima, K [1 ]
Reddy, J [1 ]
Sathyanarayana, UG [1 ]
Shigematsu, H [1 ]
Suzuki, M [1 ]
Takahashi, T [1 ]
Shivapurkar, N [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Pathol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA
关键词
D O I
10.1378/chest.125.5_suppl.97S-a
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Despite major improvements in patient management, the prognosis for patients with lung cancer remains dismal. As our knowledge of the molecular biology of cancers has increased, new targets for therapeutic interventions have been identified. In this article, we discuss some of the more recent developments in this field. They include revisiting some of the established concepts, such as retinoid metabolism and the inhibition of cyclooxygenase-2 metabolism. in addition, newer targets, such as transforming growth factor-beta signaling, Janus-activated kinase/signal transducers and activators of transcription pathway, and cell invasion are discussed. These studies demonstrate that multiple, often overlapping, mechanisms of disruption are present in lung cancer cells, presenting a plethora of molecular targets.
引用
收藏
页码:97S / 101S
页数:5
相关论文
共 29 条
[1]   TGF-β antagonists:: Why suppress a tumor suppressor? [J].
Akhurst, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (12) :1533-1536
[2]   The promise of retinoids to fight against cancer [J].
Altucci, L ;
Gronemeyer, H .
NATURE REVIEWS CANCER, 2001, 1 (03) :181-193
[3]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[4]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[5]  
El-Bayoumy K, 1999, CANCER RES, V59, P1400
[6]  
Esteller M, 2002, CANCER RES, V62, P5902
[7]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[8]   Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung [J].
Hosomi, Y ;
Yokose, T ;
Hirose, Y ;
Nakajima, R ;
Nagai, K ;
Nishiwaki, Y ;
Ochiai, A .
LUNG CANCER, 2000, 30 (02) :73-81
[9]   Cancer statistics, 2002 [J].
Jemal, A ;
Thomas, A ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (01) :23-47
[10]   Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory [J].
Jensen, PB ;
Sehested, M ;
Langer, SW ;
Hansen, HH .
CANCER TREATMENT REVIEWS, 1999, 25 (06) :377-386